{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002691","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.865344+00:00","generated_at":"2026-05-16T10:59:55.576590+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge","bullets":["Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.","Records ~$60M SG&A charge for matching donations to Good Days retinal fund in Q4 2025.","Preliminary Q4 and FY2025 financial update provided at J.P. Morgan Healthcare Conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002691","json":"https://secwatch.observer/filing/0001104659-26-002691.json","markdown":"https://secwatch.observer/filing/0001104659-26-002691.md","text":"https://secwatch.observer/filing/0001104659-26-002691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/0001104659-26-002691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/tm262861d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:55.576590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}